Giovanna Fessenden-Fairbank, Digital IP Counsel at Hamilton Brook Smith Reynolds, was recently featured in an article of the Databird Business Journal’s Crypto Law Series for...
Managing IP has released its 2025 IP Stars rankings, recognizing Hamilton Brook Smith Reynolds as a Recommended firm for Patent Prosecution, both nationally and in Massachusetts. The...
The USPTO will no longer accept petitions to make special under the Accelerated Examination program, effective July 10, 2025. This program is being discontinued due to dwindling...
John DuPré, Senior Counsel at Hamilton Brook Smith Reynolds, has been named a “Global Leader in Private Practice” in the seventh edition of World Trademark Review...
Giovanna Fessenden-Fairbank, Digital IP Counsel at Hamilton Brook Smith Reynolds, recently sat down with Randall Woods for a feature in Startup Boston, discussing how Massachusetts...
Hamilton Brook Smith Reynolds has been recognized by IAM Patent 1000 as a leading patent firm both nationally and in Massachusetts for excellence in patent prosecution. Principals...
As the country prepares to celebrate the 250th anniversary of the Battles of Lexington and Concord and the beginning of the Revolutionary War, Hamilton Brook Smith Reynolds is especially...
An intellectual property (“IP”) portfolio may include patent assets, copyrighted works, trademarks, and trade secrets. Understanding ownership, title, and cloud on title...
For the fifteenth consecutive year, World Trademark Review (WTR) 1000, the leading global review of trademark professionals, has ranked Hamilton Brook Smith Reynolds ...
Effective January 19, 2025, the United States Patent and Trademark Office has imposed an information disclosure statement (IDS) size fee based on the cumulative number of items cited...
Sam has been an integral part of the Hamilton Brook Smith Reynolds team since joining the firm in 2016. His practice includes patent, trademark, and trade secret litigation matters...
To the uninitiated, the combination of patent and US Food and Drug Administration (FDA) law applicable to life sciences deals may seem needlessly technical and perhaps a subject best...